BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,300
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,183
Regeneron Pharma Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,282
Regeneron Pharmaceuticals Analyst Ratings
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,250
Regeneron Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,242
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Regeneron Pharma Price Target Raised to $1240.00/Share From $1232.00 by RBC Capital
Oppenheimer Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,200
Regeneron Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,152 to $1,250
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,292 From $1,180, Maintains Buy Rating
Cantor Fitzgerald Raises Price Target on Regeneron Pharmaceuticals to $1,015 From $1,000
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen